Tiziana Life Sciences (NASDAQ:TLSA) Raised to Hold at Zacks Research

Tiziana Life Sciences (NASDAQ:TLSA) was upgraded by investment analysts at Zacks Research to a “hold” rating in a research note issued to investors on Tuesday,Zacks.com reports.

Other research analysts have also recently issued research reports about the stock. Weiss Ratings cut shares of Tiziana Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 29th. Wall Street Zen downgraded Tiziana Life Sciences from a “hold” rating to a “sell” rating in a research note on Saturday, April 18th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Reduce”.

Tiziana Life Sciences Stock Down 10.5%

NASDAQ TLSA opened at $1.11 on Tuesday. The stock’s 50-day moving average is $1.30 and its 200-day moving average is $1.36. Tiziana Life Sciences has a one year low of $1.04 and a one year high of $2.60.

Tiziana Life Sciences (NASDAQ:TLSA) last announced its quarterly earnings results on Friday, May 1st. The company reported ($0.28) earnings per share for the quarter. On average, equities research analysts forecast that Tiziana Life Sciences will post -0.16 EPS for the current year.

Hedge Funds Weigh In On Tiziana Life Sciences

Institutional investors have recently added to or reduced their stakes in the stock. Millennium Management LLC acquired a new position in shares of Tiziana Life Sciences during the third quarter worth $520,000. Jane Street Group LLC raised its position in shares of Tiziana Life Sciences by 968.2% during the first quarter. Jane Street Group LLC now owns 167,542 shares of the company’s stock worth $181,000 after acquiring an additional 151,858 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Tiziana Life Sciences by 413.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 110,290 shares of the company’s stock worth $164,000 after purchasing an additional 88,830 shares during the period. Bison Wealth LLC bought a new stake in Tiziana Life Sciences during the fourth quarter valued at $30,000. Finally, OMERS ADMINISTRATION Corp acquired a new position in shares of Tiziana Life Sciences in the 4th quarter valued at about $59,000.

Tiziana Life Sciences Company Profile

Tiziana Life Sciences plc (NASDAQ: TLSA) is a clinical-stage biotechnology company focused on the development of novel therapeutics in the fields of oncology, immunology and infectious diseases. Headquartered in London, with research and development operations in Cambridge, Massachusetts, the company advances both small-molecule inhibitors and monoclonal antibody candidates designed to modulate immune pathways and target tumor growth.

The company’s lead small‐molecule program, milciclib, is an oral cyclin‐dependent kinase inhibitor currently in Phase II clinical trials for hepatocellular carcinoma and certain neuroendocrine tumors.